Group 1: Stock Performance - Novavax (NVAX) closed at $6.97, with a daily increase of +1.9%, outperforming the S&P 500's gain of 0.14% [1] - Over the last month, Novavax shares decreased by 1.44%, while the Medical sector lost 1.34% and the S&P 500 gained 3.97% [1] Group 2: Upcoming Earnings - The upcoming EPS for Novavax is projected at -$0.12, indicating a 112.12% decline compared to the same quarter last year [2] - Revenue is estimated at $130.5 million, reflecting a 68.59% decrease from the corresponding quarter of the previous year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $2.65 per share, representing a +315.45% change from the previous year [3] - Revenue for the fiscal year is estimated at $1.07 billion, indicating a +56.76% change from the prior year [3] Group 4: Analyst Estimates and Rankings - Recent modifications to analyst estimates for Novavax indicate changing near-term business trends, with positive revisions suggesting optimism [4] - The Zacks Rank system, which includes estimate changes, currently ranks Novavax at 3 (Hold) [6] Group 5: Valuation Metrics - Novavax has a Forward P/E ratio of 2.58, which is a discount compared to the industry average Forward P/E of 18.51 [7] - The PEG ratio for Novavax is 0.06, significantly lower than the industry average PEG ratio of 1.54 [8] Group 6: Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Novavax, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [8][9] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [9]

Group 1 - Integra LifeSciences Holdings Corporation will release its second quarter 2025 financial results on July 31, 2025, before the market opens [1] - A conference call hosted by Integra's management team will take place at 8:30 a.m. ET on the same day [1] - A live webcast of the conference call will be available on the Investors section of the company's website [2] Group 2 - Integra LifeSciences is focused on restoring patients' lives through innovative treatment pathways and advancing patient outcomes [3] - The company offers a comprehensive portfolio of high-quality, leadership brands in surgical, neurologic, and regenerative care [3] - For more information about Integra and its products, the company encourages visiting its website [3]

Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 revenue increased between 41% and 42% compared to Q2 2024. First half of 2025 revenue increased 50-51% vs first half of 2024. EDEN PRAIRIE, Minn., July 14, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wou ...

SANTA CLARA, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the second quarter of 2025 after market close on Monday, August 4, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p ...

Pilot program designed to provide real-world evidence in the use of Tissue Health Plus’ technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced the recent launch, through its subsidiary, ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering CorMedix (CRMD) , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this pharmaceutical and medical device company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 24.71%, on average, in the last two quarters.For the last reported quarter, CorMedix came ...

DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnings ...

MONSEY, N.Y., July 14, 2025 (GLOBE NEWSWIRE) --  The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Monogram Technologies, Inc. (Nasdaq: MGRM) (“Monogram”) to Zimmer Biomet for an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share in cash if certain product development, regulatory, and revenue milestones are achieved through 2030. At least two investors have already express ...

On July 11, 2025, Andrew Hill Investment Advisors, Inc. disclosed it sold out its entire Johnson & Johnson (JNJ -0.60%) position, totaling $6.31 million in trades.What happenedAccording to a July 10, 2025 SEC filing, the firm exited its entire position in Johnson & Johnson during Q2 2025, selling all 38,037 shares for $6,308,131 in reported transaction value. Andrew Hill Investment Advisors no longer holds JNJ shares as of June 30, 2025, based on 13F disclosures.What else to knowThe sale represents a full e ...

Harrow (HROW) shares soared 11.4% in the last trading session to close at $34.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.7% gain over the past four weeks.The sudden rise in the share price of Harrow can be attributed to the positive investor mindset regarding the continued sales growth of its innovative opthalmic pharmaceutical products in the North American market, which is expected to further boost shareholder value. ...